Telix Pharmaceuticals Limited is a clinical-stage biotechnology company dedicated to the development and commercialisation of molecularly-targeted radiation (MTR) therapy. Our products seek to address major clinical unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.
Our mission is
to help patients
with cancer live longer
with better quality lives
We have released a presentation detailing the use of proceeds from our A$40m placement. This capital enables $TLX to build on the success of the last 18 months as well as prepare for our first commercial product (subject to approvals).